4:45 PM ET
8-K
Clinical Trial Data
Longeveron Clinical Trial Data
Longeveron announced updated Phase 2b ELPIS II trial results for laromestrocel in infants with hypoplastic left heart syndrome (HLHS). While the trial missed its primary efficacy endpoint of RVEF change, additional analysis showed the secondary endpoint of major adverse cardiac events (MACE) achieved statistical significance with only 1 event in the treatment arm versus 8 in the standard of care arm (P=0.043).
- Counterparty
- National Institutes of Health (NIH)